• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon executives release book for re-engineering clinical trials

Icon executives release book for re-engineering clinical trials

April 15, 2015
CenterWatch Staff

Global CRO Icon of Dublin, Ireland, has released the book Re-Engineering Clinical Trials, edited and co-authored by Brendan Buckley, Icon’s chief medical officer, and Peter Schüler, ICON’s senior vice president of global medical and safety services.

Joined by co-authors at AstraZeneca, Bayer, Boehringer Ingelheim, IBM, McGill University, the Tufts Center for the Study of Drug Development and 22 other institutes and companies, Buckley and Schüler present a collection of reforms for a progressive model of drug development, hoping to propel faster change in some businesses increasingly restrained by companies, not regulators.

In the book, Icon and industry leaders have asked and answered some critical questions about the fundamentals of clinical development.

“For example, what causes good drugs to fail? Why do so many expenditures in clinical trials not benefit patients? Have other industries already invented what we need? The answers can spur reforms of fundamental processes that, when implemented together, represent a new business model for drug development,” said Buckley.  

The editors argue that most of the reforms do not require invention of new technologies or methodologies. The necessary innovations are either available in other industries or already have received regulatory approval and are in use in clinical trials.

“Knowledge of beneficial reforms remains siloed and not widely disseminated, making it difficult to build momentum for change. This book is part of the process for stimulating evolution of businesses by presenting these as a package for a suggested way forward,” said Schüler.

The book, published by Elsevier, compiles factual reviews of critical reforms with express regulatory support, including:

  • Failure Mode and Effects Analysis (FMEA) and other techniques from outside industries
  • Centralized trial monitoring constructed through FMEA
  • Site staff hiring, training and performance analysis
  • Innovative trial designs, including use of surrogate endpoints and adaptive designs
  • Patient-centred recruitment and engagement
  • Protocol design and data mining
  • Unstructured data management
  • Connected health, the clinical trial app and patients as investigators.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing